
Hypofractionated radiotherapy shows promising long-term results in elderly patients with localized prostate cancer. In a cohort of 719 patients (median age 78.4 years), 5-year overall survival (OS) was 95.6%, cancer-specific survival (CSS) 99.2%, and metastasis-free survival (MFS) 97.3%. Toxicity rates were low, with 95.1% free from grade ≥2 gastrointestinal toxicity. These results reinforce the effectiveness of radiotherapy in elderly patients with localized prostate cancer.
Like
Save
Share